Michael J. Birrer, MD, PhD, University of Arkansas Medical Center

Upcoming Clinical Trials for Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Emerging Therapies in Recurrent Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Antibody Drug Conjugates for Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Neoadjuvant Therapy Versus Surgery for Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

New Data for Secondary Surgery in Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

PARP Inhibitors in Recurrent Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Expert Approaches for Treating Recurrent Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Emerging Combinations in the Frontline Setting of Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Patient Preference for Treatment in Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

PAOLA-1 Study Surgical Subset for Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

NCCN Guidelines and FDA Approvals for Treating Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Personalized Dosing of Niraparib in Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Treating Homologous Recombination Proficient Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Treating BRCA+ Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Need for Frontline Comparison Trials in Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Impact of HRD Status on Frontline Treatment of Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

The Impact of PAOLA-1 on Frontline Treatment of Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Biomarker-Driven Frontline Ovarian Cancer Treatment

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

An Introduction to the Discussion of Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Dr. Birrer on PARP Inhibitors in Ovarian Cancer

ByMichael J. Birrer, MD, PhD, University of Arkansas Medical Center

October 25th 2013

Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses the role of PARP inhibitors in ovarian cancer.

Dr. Birrer on the Approval Process in Ovarian Cancer

ByMichael J. Birrer, MD, PhD, University of Arkansas Medical Center

October 16th 2013

Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, explains how the endpoints of progression-free survival (PFS) and overall survival (OS) are holding back the approval of drugs for patients with ovarian cancer.